Format

Send to

Choose Destination
Cardiol Rev. 2008 May-Jun;16(3):142-53. doi: 10.1097/CRD.0b013e31815c8048.

Urotensin II: a new pharmacologic target in the treatment of cardiovascular disease.

Author information

1
Department of Medicine, UCLA Medical Center, Los Angeles, California, USA.

Abstract

Urotensin II was first identified over 30 years ago as a potent vasoconstrictor, and the identification of its receptor in the heart, lungs, blood vessels, and brain have made it a potential target for human pharmacotherapy. Current research would suggest that urotensin II plays a major role in the pathophysiology of various cardiovascular disease entities. This article discusses the biologic effects of urotensin under normal and pathophysiologic conditions, and reviews the research experiences with synthetic urotensin blockers in the treatment of various cardiovascular illnesses.

PMID:
18414185
DOI:
10.1097/CRD.0b013e31815c8048
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center